GlaxoSmithKline PLC (NYSE: GSK) reported Thursday that its fourth-quarter profit rose 66 percent, boosted by strong sales of swine flu vaccine and flu medicine, according to Associated Press.
Glaxo, the world's second largest drug maker by revenue, turned a net profit of 1.63 billion pounds ($2.6 billion) in the three months ending Dec. 31, compared to 982 million pounds a year earlier.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
The performance pushed full-year profits up 20 percent to 5.5 billion pounds.
Sales of Relenza, the company's flu drug, totaled 720 million pounds for the year, compared to just 57 million pounds in 2008. In the fourth quarter, Relenza sales rose to 256 million pounds from 13 million pounds a year earlier.
Total vaccine sales were up 30 percent for the year to 3.7 billion. The company also raised its full-year dividend by 7 percent to 61 pence.
The company said it aimed to cut expenditure by 500 million pounds by 2012, but said it would not announce a target for job reductions. Published reports have said that about 4,000 of GlaxoSmithKline's 99,000 employees worldwide might be affected.
GSK said sales for the year were up 16.5 percent to 28.4 billion pounds.
Sales gains of 16 percent in Asia Pacific and 9 percent in Europe helped offset a 13 percent drop in the United States, where Glaxo said several products suffered from generic competition.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
